Evaluation Understanding Lambert-Eaton Myasthenic Syndrome and Its Association with Small Cell Lung Cancer Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Jennifer Carlisle, MD 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Describe the pathophysiology, burden, and unmet needs associated with LEMS 5 4 3 2 1 Implement strategies to screen for SCLC and other carcinomas in patients with LEMS, given the underlying connection between LEMS and SCLC 5 4 3 2 1 Assess the mechanisms, safety, and efficacy of therapeutic options for LEMS 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree How many patients do you encounter with SCLC on a weekly basis? 10 or fewer 20 30 40 50 or more Please now rate your ability to use currently available therapies to manage SCLC. Excellent Very Good Good Fair Poor Do you intend to make any changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max As a result of this activity, I intend to make changes in the following areas as they pertain to the management of LEMS (select all that apply): Employ a greater focus on screening for LEMS in SCLC patients Utilize systemic treatment that has been found to improve symptoms in patients with LEMS Employ a greater focus on screening for tumors in all patients with LEMS Develop patient-centered management plans that underscore the importance of shared decision making and patient activation as a major component of successful treatment for LEMS Implement strategies to help overcome common barriers to care, including treatment adherence and adverse event management Integrate evidence-based guidelines for management of LEMS while supporting the translation of clinical evidence to practice Apply concepts that support the translation of clinical evidence to practice Other (please specify): Previous
